NOVOEIGHT

国: インドネシア

言語: インドネシア語

ソース: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

有効成分:

TUROCTOCOG ALFA

から入手可能:

BETA PHARMACON - Indonesia

INN（国際名）:

TUROCTOCOG ALFA

投薬量:

250 IU

医薬品形態:

SERBUK INJEKSI

パッケージ内のユニット:

DUS, 1 VIAL @ 250 IU + 1 PRE-FILLED SYRINGE PELARUT @ 4 ML + 1 ST...

製:

NOVO NORDISK A/S - Denmark

承認日:

2020-08-22

製品の特徴

STF APR 2021
Page 1 of 21
1.
NAME OF THE MEDICINAL PRODUCT
NOVOEIGHT
®
250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each powder vial contains nominally 250, 500 or 1000 IU human
coagulation factor VIII
(rDNA), turoctocog alfa.
After reconstitution NovoEight
®
contains approximately 62.5, 125 or 250 IU/ml of human
coagulation factor VIII (rDNA), turoctocog alfa.
The potency (IU) is determined using the European Pharmacopoeia (Ph.
Eur) chromogenic
assay. The specific activity of NovoEight
®
is approximately 8,300 IU/mg protein.
Turoctocog alfa (human coagulation factor VIII (rDNA)) is a purified
protein that has 1,445
amino acids with an approximate molecular mass of 166 kDA. It is
produced by recombinant
DNA technology in Chinese hamster ovary (CHO) cells and prepared
without the addition of
any human or animal derived protein in the cell culture process,
purification or final
formulation.
Turoctocog alfa is a B-domain truncated recombinant human coagulation
factor VIII (B-
domain consists of 21 amino acids of the wild type B-domain) without
any other
modifications in the amino acid sequence.
_Excipient with known effect_
The medicinal product contains 30.5 mg sodium per reconstituted vial.
For the full list of excipients, see section 6.1_._
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
White or slightly yellow powder or friable mass.
Clear and colourless solution for injection.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment and prophylaxis of bleeding in patients with haemophilia A
(congenital factor VIII
deficiency).
NovoEight
®
can be used for all age groups.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should be under the supervision of a doctor experienced in
the treatment of
haemophilia.
DISETUJUI OLEH BPOM: 30 JULI 2022
ID FERO: EREG100383VR12200014-16
STF APR 2021
Page 2 of 21
Treatment monitoring
Dur